[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 547
Citations 0
In This Issue of JAMA
September 6, 2016


JAMA. 2016;316(9):897-899. doi:10.1001/jama.2015.14458

Spontaneous and frequent epistaxis is a common manifestation of hereditary hemorrhagic telangiectasia (HHT). In a randomized placebo-controlled trial involving 80 patients with HHT, Dupuis-Girod and colleagues assessed the efficacy of different doses of intranasal bevacizumab—an angiogenesis inhibitor—on nosebleed duration. The authors report that compared with placebo, treatment with bevacizumab nasal spray—3 doses of 25 mg, 50 mg, or 75 mg per spray administered at 14-day intervals for a total treatment duration of 4 weeks—did not reduce epistaxis duration in the 3 consecutive months after the end of treatment.

First Page Preview View Large
First page PDF preview
First page PDF preview